Clustering of lymphoid neoplasms by cell of origin, somatic mutation and drug usage profiles: a multi-trait genome-wide association study - Takeaways - MDSpire

Clustering of lymphoid neoplasms by cell of origin, somatic mutation and drug usage profiles: a multi-trait genome-wide association study

  • By

  • Murat Güler

  • Federico Canzian

  • August 29, 2025

  • 0 min

Share

  • 1

    Lymphoid neoplasms comprise over 60 distinct entities and are among the most common cancers globally.

  • 2

    Genome-wide association studies have identified shared and subtype-specific genetic loci for lymphoid neoplasms.

  • 3

    Multi-trait GWAS methods exploit pleiotropy to enhance statistical power by aggregating related phenotypes.

  • 4

    Hierarchical clustering was used to create phenoclusters based on cell of origin, somatic mutations, and drug usage.

  • 5

    The study utilized large biobank cohorts to identify genetic risk loci and characterize multi-trait signals associated with lymphoid neoplasms.

Original Source(s)

Clustering of lymphoid neoplasms by cell of origin, somatic mutation and drug usage profiles: a multi-trait genome-wide association study

  • by Murat Güler, Federico Canzian

  • August 29, 2025

Related Content

This Week’s Biopharma News: Amgen Deepens US Manufacturing Push

The company adds $300 million to its Puerto Rico biologics site as Pfizer reports Phase 3 myeloma data, J&J advances a dual-pathway IBD antibody, and BioNTech streamlines production

  • May 12, 2026

  • 7 min
An ASCO preview: What to watch for at cancer research’s big meeting

Differential expression of immune activation markers in T cells from patients with multiple myeloma